INTELLIA THERAPEUTICS, INC. Marketable Securities (Current)
INTELLIA THERAPEUTICS, INC. (NTLA) had Marketable Securities (Current) of $331.63 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $331.63M.
- 2026-03-31: Marketable Securities, Current $241.29M.
- 2025-12-31: Marketable Securities, Current $294.42M.
- 2025-09-30: Marketable Securities, Current $317.65M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $331.63M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $241.29M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $294.42M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $317.65M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $303.48M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $376.87M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $412.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | $537.62M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $560.22M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $619.32M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $685.48M 10-K · filed 2025-02-27 |
| 2023-09-30 | $686.76M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $736.27M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $639.39M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $669.12M 10-K · filed 2024-02-22 |
| 2022-09-30 | $687.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $726.49M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $721.87M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $625.28M 10-K · filed 2023-02-23 |
| 2021-09-30 | $463.53M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $399.14M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $442.52M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $437.35M 10-K · filed 2022-02-24 |
| 2020-09-30 | $228.20M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $75.12M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $169.27M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $222.50M 10-K · filed 2021-02-26 |
| 2019-09-30 | $247.48M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $221.96M 10-Q · filed 2019-08-01 |
| 2018-12-31 | $255.20M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |